- Home
- RRGB vs AGEN Comparison
RRGB vs AGEN Comparison
Compare RRGB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- AGEN
- Stock Information
- Founded
- RRGB 1969
- AGEN 1994
- Country
- RRGB United States
- AGEN United States
- Employees
- RRGB N/A
- AGEN N/A
- Industry
- RRGB Restaurants
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRGB Consumer Discretionary
- AGEN Health Care
- Exchange
- RRGB Nasdaq
- AGEN Nasdaq
- Market Cap
- RRGB 88.7M
- AGEN 87.7M
- IPO Year
- RRGB 2002
- AGEN 2000
- Fundamental
- Price
- RRGB $6.30
- AGEN $5.29
- Analyst Decision
- RRGB Strong Buy
- AGEN Buy
- Analyst Count
- RRGB 4
- AGEN 4
- Target Price
- RRGB $11.88
- AGEN $13.00
- AVG Volume (30 Days)
- RRGB 620.3K
- AGEN 1.7M
- Earning Date
- RRGB 08-21-2025
- AGEN 08-07-2025
- Dividend Yield
- RRGB N/A
- AGEN N/A
- EPS Growth
- RRGB N/A
- AGEN N/A
- EPS
- RRGB N/A
- AGEN N/A
- Revenue
- RRGB $1,252,370,000.00
- AGEN $99,524,000.00
- Revenue This Year
- RRGB $0.04
- AGEN $12.69
- Revenue Next Year
- RRGB N/A
- AGEN N/A
- P/E Ratio
- RRGB N/A
- AGEN N/A
- Revenue Growth
- RRGB N/A
- AGEN N/A
- 52 Week Low
- RRGB $2.50
- AGEN $1.38
- 52 Week High
- RRGB $7.66
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- RRGB 65.37
- AGEN 55.11
- Support Level
- RRGB $5.41
- AGEN $4.34
- Resistance Level
- RRGB $6.48
- AGEN $5.05
- Average True Range (ATR)
- RRGB 0.43
- AGEN 0.38
- MACD
- RRGB 0.02
- AGEN -0.09
- Stochastic Oscillator
- RRGB 89.94
- AGEN 60.80
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).